CLClinicLens

Surgery

[Correspondence] COLOR III: widespread TaTME dissemination demands a LAPCO-equivalent framework | ClinicLens

We read with great interest the short-term outcomes of transanal total mesorectal excision (TaTME) for mid and low rectal cancer in Jurriaan B Tuynman and colleagues’ COLOR III trial,1 and the accompanying Comment by Patricia Sylla.2 The reduction in conversion rates versus lapar

Medical Literature · Updated

← Back to articles
This standalone article is served from the ClinicLens content archive.

If the embedded page does not load in your browser, open it directly.